WO2023034870 - COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION
National phase entry:
Publication Number
WO/2023/034870
Publication Date
09.03.2023
International Application No.
PCT/US2022/075772
International Filing Date
31.08.2022
Title **
[English]
COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION
[French]
COMPOSÉS ET MÉTHODES POUR RÉDUIRE L'EXPRESSION DE DMPK
Applicants **
IONIS PHARMACEUTICALS, INC.
Inventors
RIGO, Frank
DWYER, Chrissa, A.
Priority Data
63/239,765
01.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5577 | |
| EPO | Filing, Examination, Granting | 119636 | |
| Japan | Filing, Examination, Granting | 4923 | |
| South Korea | Filing, Examination, Granting | 8809 | |
| USA | Filing, Examination, Granting | 44960 |
Total:
183,905
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are oligomeric compounds, methods, and pharmaceutical compositions for DMPK the amount or activity of DMPK RNA in a cell or animal, and in certain instances reducing the amount of DMPK protein in a cell or animal. Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat type 1 myotonic dystrophy.[French]
L'invention concerne des composés oligomères, des méthodes et des compositions pharmaceutiques destinés à réduire la quantité ou l'activité de l'ARN DMPK dans une cellule ou chez un animal et, dans certains cas, à réduire la quantité de protéines DMPK dans une cellule ou chez un animal. De tels composés oligomères, des méthodes et des compositions pharmaceutiques sont utiles pour traiter la dystrophie myotonique de type 1.